Kimera

What Kimera does

Kimera S.r.l. is an Italian preclinical-stage biotechnology company founded in 2019 and headquartered in Naples, within the laboratories of CEINGE Biotecnologie Avanzate Franco Salvatore. The company develops gene therapies for inherited metabolic disorders, with a primary focus on familial hypercholesterolemia — a severe inherited lipid disorder most commonly caused by mutations in the LDL receptor (LDLR) gene. Kimera's lead therapeutic, Kimeragene, is a muscle-targeted gene therapy that delivers a genetic construct encoding a proprietary chimeric fusion protein combining the LDLR extracellular domain with transferrin, packaged into helper-dependent adenoviral (HD-Ad) vectors under a muscle-specific promoter to enable sustained systemic production and bypass of the defective LDLR clearance pathway via transferrin receptor-mediated uptake.

The company's underlying technology is an engineered chimeric protein platform that pairs a binding domain recognizing a disease-causing substrate with a trafficking domain that redirects the substrate to alternative cellular clearance pathways. This modular architecture is intended to support rapid development of additional therapies across metabolic disorders by swapping binding domains. In March 2026, Kimera and collaborators published preclinical data in Molecular Therapy showing that a single intramuscular administration of the therapy in LDLR-deficient mice produced sustained lipid improvements and significant reduction of aortic atherosclerosis for up to 12 weeks, with restoration of LDL uptake in LDLR-deficient cells and no major systemic toxicity observed.

Kimera is pre-revenue. Its business model is oriented toward research collaborations with academic institutions and, ultimately, licensing, co-development, or acquisition transactions with pharmaceutical partners once clinical-stage milestones are achieved. The company operates through a small scientific team (11-50 employees) anchored within CEINGE and supported through the EXTEND Italian National Technology Transfer Hub (promoted by CDP Venture Capital in partnership with Evotec). No disclosed funding rounds, licensing deals, clinical trials, or IND filings were identified in the available data.

Name

Kimera

Legal name

Kimera S.r.l.

Website

https://kimerabio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Kimera S.r.l. is an Italian preclinical-stage biotech developing gene therapies for inherited metabolic disorders, with its lead asset Kimeragene targeting homozygous familial hypercholesterolemia via a muscle-directed chimeric LDLR-transferrin fusion protein delivered by helper-dependent adenoviral vectors.

Ownership category

akta.pro rank

Product category

Gene Therapy Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Gene therapy development
• Chimeric protein engineering
• Familial hypercholesterolemia treatment
• Metabolic disorder biotech
• Preclinical gene therapy

Headquarters

HQ city

Naples

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Gene Therapy Development: Pre-revenue company focused on R&D for protein-based treatments. Revenue model would likely involve licensing, partnerships, or acquisition upon successful clinical development.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Kimera develops protein-based gene therapies for inherited metabolic disorders, with its lead product Kimeragene delivering a chimeric fusion protein (LDLR extracellular domain linked to transferrin) via helper-dependent adenoviral vectors with a muscle-specific promoter to restore LDL clearance in patients with familial hypercholesterolemia. The underlying Engineered Chimeric Protein Platform combines binding domains with trafficking domains to redirect disease-causing substrates to alternative cellular clearance pathways, enabling modular development across multiple metabolic disorders. The company is preclinical-stage and does not yet sell commercial products.

Product overview

Kimera is a biotech company developing gene therapies for metabolic disorders, with its primary therapeutic product being Kimeragene. The platform is built on engineered chimeric proteins that combine binding domains for substrate recognition with trafficking domains for directing molecules to cellular clearance pathways. This modular approach enables the development of mechanism-based therapies, with the lead indication targeting familial hypercholesterolemia through a functional bypass strategy that restores LDL clearance via transferrin receptor-mediated uptake.

Differentiator

Problem solved

Functional benefit

Brands

• Kimeragene: Gene therapy designed to restore physiological LDL clearance in patients with familial hypercholesterolemia, including those with severely impaired LDL receptor (LDLR) function. The therapy delivers a genetic construct encoding a proprietary chimeric fusion protein using helper-dependent adenoviral vectors.

Products and services

• Kimeragene Preclinical muscle-targeted gene therapy that delivers a genetic construct encoding a proprietary chimeric fusion protein (LDLR extracellular domain linked to transferrin) using helper-dependent adenoviral vectors with a muscle-specific promoter. Designed to restore physiological LDL clearance in patients with familial hypercholesterolemia, including those with severely impaired LDLR function who respond inadequately to current lipid-lowering treatments.
• Engineered Chimeric Protein Platform Modular biotechnology platform that combines engineered chimeric proteins featuring a binding domain recognizing disease-causing substrates with a trafficking domain that redirects substrates to alternative cellular clearance pathways. Designed to enable rapid development of therapies across multiple metabolic disorders by swapping binding domains for different substrates.

Quantifiable outcome

• Sustained lipid improvements and reduced aortic atherosclerosis for up to 12 weeks in LDLR-deficient mice preclinical model
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• EXTEND (CDP Venture Capital + Evotec)coreStrategic or Co-development PartnerEXTEND is the Italian National Technology Transfer Hub dedicated to the biopharmaceutical sector, promoted by CDP Venture Capital in partnership with Evotec. Supported the preclinical gene therapy study for familial hypercholesterolemia.
• CEINGE Biotecnologie Avanzate Franco SalvatorecoreStrategic or Co-development PartnerResearch center in Naples where Kimera conducts its R&D activities within the laboratories. Provides infrastructure and processes for advancing the company's platform from concept to validation.

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Verve Therapeutics: Verve Therapeutics is a clinical-stage genetic medicines company developing in vivo gene editing therapies for cardiovascular disease, including familial hypercholesterolemia. Directly comparable to Kimera as both pursue one-time, gene-based interventions that durably lower LDL cholesterol in FH patients.
• Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage gene therapy company with a leading program in cardiovascular disease, including FH. Highly comparable as both are advancing AAV-based gene therapies targeting inherited lipid disorders with similar patient-focused positioning.

Broad incumbents

• REGENXBIO: REGENXBIO is a clinical and commercial-stage gene therapy company with a leading AAV delivery platform used across multiple rare disease programs. Comparable as an established AAV-based gene therapy company whose technology platform and manufacturing infrastructure are relevant benchmarks for Kimera's HD-Ad approach.
• uniQure: uniQure is a commercial-stage gene therapy company with AAV-based therapies approved or in late-stage development for rare diseases. Comparable as a mature gene therapy company navigating the same regulatory, manufacturing, and commercialization pathways relevant to Kimera's preclinical program.

Emerging players

• Intellia Therapeutics: Intellia Therapeutics is a clinical-stage company developing in vivo CRISPR/Cas9 gene editing therapies, including cardiovascular programs. Comparable as a developer of in vivo genetic medicines for metabolic disorders, representing both a peer technology approach and a future competitive threat in cardiovascular indications.
• MeiraGTx: MeiraGTx is a clinical-stage gene therapy company with proprietary viral vector manufacturing and a pipeline spanning rare metabolic and ocular diseases. Comparable as a small-cap gene therapy company combining a proprietary platform with internal manufacturing, illustrating a viable scale-up pathway for Kimera.
• Tenaya Therapeutics: Tenaya Therapeutics develops genetic medicines for heart disease, with programs spanning gene therapy, gene editing, and cellular regeneration. Comparable as a cardiovascular-focused genetic medicines company, though more advanced and with broader indication scope than Kimera.
• Beam Therapeutics: Beam Therapeutics is a clinical-stage company developing base editing therapies for genetic diseases, with cardiovascular programs in development. Comparable as a genetic medicines developer pursuing one-time treatments for inherited metabolic disorders, directly relevant to the FH competitive landscape.
• Solid Biosciences: Solid Biosciences is a clinical-stage genetic medicines company developing AAV-based gene therapies for rare diseases. Comparable as a small-cap, gene-therapy-focused biotech advancing rare disease programs through early-stage clinical development.
• Aavantgarde Bio: Aavantgarde Bio is an early-stage European genetic medicines company developing AAV-based therapies for inherited diseases. Comparable as a similarly sized European-focused gene therapy startup targeting rare monogenic disorders, offering a close peer for stage and geographic context.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kimera